

**Dissection and manipulation of antigen-specific T cell responses** Schepers, K.

# **Citation**

Schepers, K. (2006, October 19). *Dissection and manipulation of antigen-specific T cell responses*. Retrieved from https://hdl.handle.net/1887/4920



**Note:** To cite this publication please use the final published version (if applicable).

# **Chapter 1**

# **Dissection of cytotoxic and helper T cell responses**

Koen Schepers, Ramon Arens, and Ton N.M. Schumacher

*Cell. Mol. Life Sci. 62: 2695-2710 (2005)* 

# **CMLS Cellular and Molecular Life Sciences**

# **Review**

# **Dissection of cytotoxic and helper T cell responses**

**K. Schepers, R. Arens and T. N. M. Schumacher\***

Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam (The Netherlands), Fax: +31 20 5122057, e-mail: t.schumacher@nki.nl

Received 16 June 2005; received after revision 2 August 2005; accepted 15 August 2005

Abstract. Cytotoxic (CD8<sup>+</sup>) and helper (CD4<sup>+</sup>) T cells play a crucial role in resolving infections by intracellular pathogens. The development of technologies to visualize antigen-specific T cell responses in mice and men over the past decade has allowed a dissection of the formation of adaptive T cell immunity. This review gives a brief overview of the currently used detection techniques

and possible future additions. Furthermore, we discuss our current understanding of the formation of antigenspecific T cell responses, with particular attention to the similarities and differences in CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses, the functional heterogeneity within responder T cell pools and the regulation of CD8+ T cell responses by dendritic cells and CD4<sup>+</sup> helper T cells.

**Key words.** CD4<sup>+</sup> T lymphocytes; CD8<sup>+</sup> T lymphocytes; T cell memory; antigen presenting cells; dendritic cells; infection; T cell differentiation; T cell migration.

### **Introduction**

T cells are crucial for fighting pathogens such as viruses and bacteria. Cytotoxic (CD8+ ) T cells recognize peptides bound to the major histocompatibility complex (MHC) class I molecules that are present on virtually all nucleated cells. CD8<sup>+</sup> T cells are specialized in tracking down infected cells with the aim to destroy these cells, including the residing pathogens. The main mechanism used by  $CD8^+$  T cells to attack infected cells is the induction of apoptosis, either through ligand-induced deathreceptor triggering, or via the release of perforins and granzymes. In addition, CD8+ T cells secrete cytokines such as interferon- $\gamma$  (IFN- $\gamma$ ) and tumor necrosis factor (TNF) that can enhance antigen (Ag) presentation and mediate anti-pathogenic effects, for instance by interfering with viral/bacterial replication. Helper (CD4+) T cells recognize peptides complexed with MHC class II molecules that are only expressed on so-called professional Ag presenting cells (APCs), such as dendritic cells (DCs), macrophages and B cells. CD4+ T cells are specialized in providing supporting signals to other cell types within the immune system such as macrophages, B cells and CD8+ T cells, in the form of cytokines and through direct interactions.

During T cell development in the thymus each thymocyte creates an essentially unique T cell receptor (TCR) by rearrangement of functional TCR- $\alpha$  and - $\beta$  genes from pools of discontinuous TCR gene segments. This process of TCR gene recombination leads to the formation of a pool of T cells expressing a broad repertoire of TCRs that collectively can recognize millions of different peptide-MHC (pMHC) complexes. The process of recombination not only results in TCRs that have the potential to recognize a foreign peptide bound to MHC, but also in TCRs that fail to recognize MHC altogether, or that can recognize self-peptides bound to MHC. To mould

<sup>\*</sup> Corresponding author.

the repertoire of T cells towards a pool of cells that can potentially recognize foreign pMHC complexes and that is not self-reactive, T cells undergo an intrathymic selection process. Thymocytes that express TCRs with high affinity for self-pMHC undergo apoptosis, thymocytes with no affinity for endogenous pMHC complexes die of neglect, and consequently only thymocytes that express TCR with low affinity for self-pMHC differentiate into CD4+ and CD8+ T cells and are exported to the periphery. In the periphery, T cells continuously migrate through lymphoid organs, where they scan the pool of peptides presented by APCs.

#### Techniques to visualize Ag-specific T cell responses

Traditional techniques to monitor Ag-specific T cell responses measured the capacity of pools of T cells to react to Ag, either in the form of Ag-induced proliferation, cytotoxicity or cytokine secretion. In the past decade these techniques have in large part been replaced by technologies that allow the visualization of Ag-specific T cells at the single cell level. Of these techniques, in particular the flow cytometry-based techniques, which also allow further characterization and/or isolation of Ag-specific T cells, have become valuable and are the main focus of this review.

#### **MHC multimers**

The analysis of Ag-specific T cell responses using pMHC multimers is based on the very convincing argument that if the binding of T cells to a given pMHC complex defines their Ag specificity, a recombinant version of this pMHC complex should be an ideal tool to detect such cells. Following the first description by Altman et al. some 10 years ago, pMHC-based reagents have become an invaluable tool for the analysis of Ag-specific T cell responses [1]. For the generation of pMHC class I complexes, both the MHC class I heavy chain and light chain (b2-microglobulin) are generally produced in *Escherichia coli* cells and folded in vitro in the presence of a specific peptide. For pMHC class II complexes, the complex of the MHC chains with Ag peptide is generally produced in eukaryotic expression systems, but variations on these themes are possible [2]. As the interaction between a TCR and its cognate pMHC complex is characterized by a fast off-rate [3], pMHC complexes need to be multimerized for efficient detection of Agspecific T cells. Multimerization is most often achieved using the biotin-streptavidin interaction, resulting in the formation of tetrameric pMHC complexes [1], but other ways of multimerization are possible [2]. Coupling of a fluorochrome to the multimeric pMHC complex is used to allow the visualization of Ag-specific T cells most commonly by flow cytometry but also in situ [4] or on pMHC microarrays [5, 6].

Although MHC class II multimers can be generated by in vitro refolding of at least some MHC class II alleles, the yield of this procedure is low. The group of Kappler and Marrack provided an alternative to this strategy by covalently linking the peptide of interest to the  $\beta$ -chain of MHC class II, thereby ensuring binding of the peptide into the peptide-binding groove during production in eukaryotic cells [7, 8]. This approach has successfully been used to generate both human and mouse MHC class II multimers [9, 10], and modifications of this technique have now also been used to generate MHC molecules that can be complexed with a peptide of choice in vitro [11, 12].

A major advantage of MHC-multimer technology is that it allows detection of Ag-specific T cells directly ex vivo, without requiring any in vitro restimulation [1]. This can for instance be used to correlate the phenotype of Ag-specific T cells with certain disease states. Although the low frequency of Ag-specific CD4<sup>+</sup> T cells often complicates the ex vivo phenotypic characterization of these cells, it was recently shown that isolation of infrequent MHC multimer-positive CD4<sup>+</sup> T cells with magnetic beads allows their phenotypic characterization in at least some settings [11, 13]. It should be noted though that binding of MHC class II multimers to CD4<sup>+</sup> T cells is generally achieved by incubation of the cells with these reagents at 37 ºC for several hours and one should take into account the possibility that TCR triggering induced by MHC multimer binding may result in up- or downregulation of phenotypic markers such as early activation markers. In addition, it is noted that MHC multimers can in some cases fail to detect a fraction of Ag-specific T cells (reviewed in [2]), such as highly activated T cells that have a reduced TCR expression and T cells with a lower avidity for the relevant pMHC complex. Again, this problem appears to be more common for MHC class II multimers than for MHC class I multimers.

#### **Functional assays**

Whereas MHC multimers detect Ag-specific T cells on the basis of the pMHC-TCR interaction, functional assays monitor the effects of this interaction on T cells. At present, three techniques are available for the detection of Ag-induced cytokine production at the single cell level. The shared characteristic of these techniques is that they aim to ensure that cytokines that are produced by the cell upon antigen encounter do not dissipate into the medium upon secretion. The most frequently used functional test to detect Ag-specific T cells on a per cell basis is the intracellular cytokine staining (ICS) assay. In this assay, T cells are incubated for several hours in the presence of Ag plus an intracellular protein transport inhibitor (e. g. brefeldin A) to ensure accumulation of the Ag-induced cytokine inside the cells. Subsequent permeabilization and staining for the cytokine of interest then allows the detection of functional Ag-specific T cells at the single cell level by conventional flow cytometry. While the ICS assay is generally used to monitor cytokine secretion following ex vivo Ag encounter, a recent study demonstrates that administration of BrefoldinA to mice also allows the measurement of in vivo cytokine production [14]. Although combined cytokine and MHC multimer stainings have been performed, the stimulation with Ag plus incubation with brefeldin A that is needed to allow cytokine detection leads to down-regulation of the TCR, often to such an extent that it hampers T cell detection by MHC multimer staining. For unknown reasons, this phenomenon is more pronounced for mouse T cells than for human T cells.

An alternative technique for the visualization of Ag-specific T cells based on cytokine secretion is the ELISPOT assay. In this assay, T cells are stimulated with peptide for a brief period, while being trapped in an agar gel. Subsequently, Ag-induced secretion of cytokines is detected by antibody staining. The main advantage of this technique is that it is extremely sensitive, enabling the detection of cells that are present at very low frequencies. However, because ELISPOT does not allow the further characterization and isolation of the Ag-specific T cells, its value is mostly restricted to the counting of Ag-specific T cells.

A third approach for the detection of cytokine-secreting T cells at the single cell level makes use of a cell surface affinity matrix consisting of a bispecific antibody recognizing the cytokine of interest and the CD45 molecule that is widely expressed on lymphocytes [15]. The advantage of this approach is that the cytokine-secreting cells maintain their viability during the assay, allowing T cell isolation (using flow cytometric cell sorting or magnetic bead isolation) and further characterization.

Apart from these three assays that detect T cell function by monitoring cytokine production, Ag-specific CD8+ T cells may also be detected at the single cell level based on Ag-induced degranulation. In this assay, cells are stained with an antibody specific for CD107 (LAMP-1), a molecule that is present in the membrane of cytotoxic granules and is exposed on the cell surface upon Ag-induced degranulation [16]. Although cell surface exposure of CD107 is a marker for degranulation, CD107-positive T cells are not necessarily cytotoxic, as cytotoxicity depends on the protein content of the cytotoxic granules [17]. As is the case for the cytokine capture assay, viable Ag-specific T cells may be isolated by monitoring Aginduced degranulation.

It is important to note that the several functional assays and MHC multimer staining should be considered complementary rather than substitute technologies. Specifically, the total number of Ag-specific T cells

may be substantially greater than the number of Agspecific T cells capable of performing a given effector function. For instance, T cells that have only partially differentiated upon Ag encounter may not be able to perform specific effector functions, and even when fully differentiated, the capacity of  $CD4^+$  T cells to produce specific cytokines is dependent on the differentiation pathway that was followed (further discussed below). Finally, during chronic infections, the capacity to produce specific cytokines may be lost. Specifically, the parallel use of MHC multimer staining and intracellular cytokine staining has revealed that in HIV-infected individuals HIV-specific  $CD8<sup>+</sup>$  T cells do not disappear, but rather lack the potential to produce IFN- $\gamma$  [18]. Thus, before setting out to measure Ag-specific T cell frequencies, one should consider whether an analysis of Ag-specific T cell numbers or of Ag-specific T cell activity is most relevant for a particular study, and in most cases the parallel use of MHC multimer staining and functional assays is likely to be most valuable.

#### **Counting Ag-specific T cells**

The first important observation made through the use of MHC multimer and intracellular IFN- $\gamma$  staining was that the frequencies of Ag-specific  $CD8<sup>+</sup>$  T cells present during an acute viral infection are much higher than previously thought [19–23]. Earlier studies had established that the fraction of T cells that went through cell division during an acute infection was high. However, it had long been assumed that the majority of these cells were socalled bystander T cells that did not recognize epitopes associated with the ongoing infection. MHC multimer analysis of CD8+ T cell responses during acute infections disproved this hypothesis by demonstrating that the vast majority of proliferating cells that are found during an acute infection are specific for the infectious agent [19, 23]. At the peak of the Ag-specific  $CD8<sup>+</sup> T$  cell response, up to  $70\%$  of  $CD8^+$  T cells were found to be Ag-specific in mice infected with lymphocytic choriomeningitis virus (LCMV) or influenza virus.

Although studies using MHC class I multimers showed that the frequencies of Ag-specific CD8<sup>+</sup> T cells had greatly been underestimated, studies using MHC class II multimers suggest that this may not be the case for CD4+ T cell responses. Only in a few instances can Agspecific CD4<sup>+</sup> T cells be readily detected directly ex vivo, for example in synovial fluid of patients with rheumatoid arthritis or lyme disease [24, 25] or in draining lymph nodes of vaccinated mice [26, 27]. In murine viral infection models such as Moloney murine sarcoma/leukaemia virus (MoMSV) and LCMV infection, reasonably high frequencies of CD4+ T cells specific for the immunodominant epitope (approximately 1% and 10% respectively)



Figure 1. Ag-specific T cell responses are characterized by three phases. In the priming/expansion phase, T cells proliferate and differentiate into effector cells that have cytotoxic capacity and express high levels of IFN-y. In the following contraction phase, Ag-specific T cell numbers decline to 5–10% of the numbers observed at the peak of the response. The remaining population forms the memory T cell pool that is maintained a long time and mediates long-term protection. The numbers indicate the fold increase/decrease in Agspecific T cell numbers during the priming/expansion and contraction phase, respectively.

have been detected [10, 28]. However, in other cases in vitro restimulation of blood cells is often needed to allow for the detection of MHC class II multimer-positive cells [12, 25, 29, 30].

Furthermore, even in cases where CD4<sup>+</sup> T cell responses can be detected directly ex vivo, the size of these responses is substantially smaller than that of the CD8+ T cell responses that occur in parallel. Specifically, quantification of CD4+ and CD8+ T cell responses by MHC multimer staining in mice undergoing MoMSV or LCMV infection showed that at the peak of the T cell response about 20- 35 times more Ag-specific CD8+ T cells are found than Ag-specific  $CD4^+$  T cells [10, 28]. Similar results were obtained when LCMV-specific CD4+ and CD8+ T cell responses were analyzed by intracellular IFN- $\gamma$  staining [31]. Intracellular IFN- $\gamma$  staining has likewise been used to demonstrate that Ag-specific  $CD4^+$  T cell responses are much less prominent than Ag-specific CD8+ T cell responses during infection with the intracellular bacterium *Listeria monocytogenes* (LM) in mice and Epstein Barr virus (EBV) and cytomegalovirus (CMV) infections in humans [32–34]. This difference in the magnitude of Agspecific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses could in theory be due to the fact that MHC class I complexes have a broader expression pattern than MHC class II complexes, which are primarily expressed by APC. More likely, in vitro experiments by Foulds et al. demonstrated that the smaller size of Ag-specific  $CD4^+$  T cell responses may be explained by a difference in the size of the proliferative burst that  $CD4^+$  and  $CD8^+$  T cells undergo upon Ag encounter [35]. This difference is likely to be at least in

part cell-intrinsic as it can be documented in simplified in vitro culture systems. However, it remains possible that the capacity of CD4<sup>+</sup> and CD8<sup>+</sup> T cells to respond to environmental signals such as cytokines and/or co-stimulatory molecules plays an additional role in vivo.

The smaller size of immunodominant Ag-specific CD4+ T cell responses may in part be compensated by a greater diversity of the Ags that are recognized within a pathogen-specific  $CD4^+$  T cell response.  $CD8^+$  T cells that recognize different epitopes presented on the same APC appear to compete with each other in at least some mouse models [36–38]. In contrast, one study demonstrated that CD4+ T cells that recognize distinct Ags presented by the same APC can help each other [39]. As a consequence of intraclonal competition, CD8+ T cell responses may generally be restricted to a restricted set of epitopes, whereas a pathogen-specific CD4<sup>+</sup> T cell response could conceivably recognize a broader repertoire of epitopes, each of which would only constitute a small part of the response.

Whereas the use of MHC class I multimer and IFN- $\gamma$ staining has demonstrated that dividing/effector CD8+ T cells that are present during an ongoing immune response are Ag-specific rather than bystander cells, it is still unclear whether the same holds true for Ag-specific CD4<sup>+</sup>T cell responses. Specifically, CD4+ T cells that recognize the immunodominant epitope of the MoMSV virus only accounted for about  $1\%$  of the CD4<sup>+</sup> T cells that were present in MoMSV-induced lesions [10]. If T cells that recognize the immunodominant epitope constitute a substantial part of the total pathogen-specific CD4<sup>+</sup> immune response, as has been described for CD8+ T cell responses (but see note on interclonal help above), a significant percentage of the lesion-infiltrating CD4+ T cells are likely not to be Ag-specific. Interestingly, during LCMV infection at least 80% of the CD4<sup>+</sup> T cells that divide in the spleen have been shown to be specific for two immunodominant MHC class II restricted epitopes of LCMV [28]. At first glance, these data appear in contradiction with the analysis of the MoMSV-specific CD4<sup>+</sup> T cell response. Conceivably, the involvement of bystander CD4+ T cells might be small during LCMV infection and large during MoMSV infection. Alternatively, a large fraction of CD4+ T cells that are attracted to an effector site might not be pathogen-specific, whereas the majority of dividing CD4+ T cells present in lymphoid organs during an infection are specific for this pathogen.

## **Three separate phases during Ag-specific T cell responses**

Upon activation, Ag-specific T cells rapidly expand and differentiate into effector cells that express high levels of effector cytokines and in case of CD8+ T cells also have cytotoxic capacity (fig. 1) [40–441. Following this activation/expansion phase, a contraction phase ensues, in which Ag-specific T cell numbers decline to 5–10% of the number observed at the peak of the response (reviewed in [45]). The remaining population forms the memory T cell pool that stays present for longer periods of time (memory phase), and can mediate long-term protection (reviewed in [46]). These three phases of clonal expansion, contraction and memory formation are found in response to many different types of acute infection and for different Ags within the same pathogen, indicating a common pathway for memory T cell formation.

#### **Activation/expansion phase**

Immature APC require two ingredients to become capable of stimulating a robust T cell response (fig. 2A). First, at the site where pathogens invade the body, APCs, primarily DCs, can internalize pathogen-infected dying cells and in some cases also free pathogen, providing a source of Ag that can subsequently be presented in the context of MHC molecules [47]. Second, APCs possess a set of receptors that recognize molecules or molecular patterns that are associated with infection or cell death. A first class of these receptors is formed by the patternrecognition receptors, such as the Toll-like receptors [47–49] that recognize pathogen-associated molecular patterns (PAMPs). In addition, APCs appear to express receptors that recognize endogenous indicators of 'danger' (such as uric acid) that are released by dying or infected cells [50, 51]. Triggering of these receptors leads to activation of APCs [47–51] and induces the release of inflammatory mediators such as IFN- $\alpha$ / $\beta$ , TNF and IL-1 by tissue (-resident) cells, leading to further activation of DCs [48]. Upon activation, APCs gain an increased capacity to migrate to lymphoid organs, allowing them to subsequently activate naïve T cells [47].

Activation of naïve T cells upon APC encounter not only depends on the number of pMHC complexes that are present on the APC and the affinity of the TCR for the pMHC complex (pMHC-TCR interaction, 'signal 1'), but also on signals provided by the APC in the form of costimulation ('signal 2') and cytokines ('signal 3')  $(fig. 2B)$ . Costimulation can be defined as triggering of receptors on T cells by costimulatory ligands expressed by activated APCs that leads to enhanced TCR-driven expansion. The best-defined costimulatory molecules belong either to the immunoglobulin-like CD28 family or to the TNF receptor family. The costimulatory molecules and ligands of these families are differently expressed throughout an infection. For instance, whereas some receptors are expressed on naïve T cells (such as CD27 and CD28), other costimulatory molecules are only expressed on the cell surface at different time points



Figure 2. Activation of Ag-specific CD8+ T cells by APC. (A) Ag uptake by APCs. Upon pathogen encounter, APCs internalize pathogen-infected dying cells/free pathogen, providing a source of Ag that can subsequently be presented in the context of MHC molecules. In addition, APCs express receptors that recognize indicators of 'danger' (such as pattern recognition receptors), the triggering of which leads to APC activation. (B) APC-T cell interaction. Depending on the amount and type of pathogen, APCs require help from  $CD4^+$  T cells to activate  $CD8^+$  T cells. This help by  $CD4^+$  T cells is provided via signals, such as CD40L and IFN- $\gamma$ , that stimulate APCs to increase the expression of costimulatory ligands and the secretion of stimulatory cytokines (such as IL-12). In addition, CD4+ T cells may directly activate CD8+ T cells by membrane-bound ligands and/or cytokines.

after T cell activation (e. g. OX40, 4-1BB) [52]. The consequences of costimulation range from enhanced survival and increased proliferation to differentiation of Ag-specific T cells and can vary between different costimulatory molecules. For instance, engagement of CD28 enhances IL-2 production [53], whereas signaling through inducible costimulator (ICOS) leads to increased production of IL-10 [54]. In the absence of costimulation, Ag-loaded APCs are generally non-stimulatory and may even tolerize responding T cells [55].

Cytokines produced by APCs can also affect both the size and the quality of the ensuing T cell response. For example, recognition of virus and bacteria-derived PAMPs leads APCs to produce IL-12 that drives the generation of so-called type 1 T helper cells (Th1 cells), which express IFN- $\gamma$  and promote cell-mediated immunity [56, 57]. In contrast, recognition of parasites stimulates APCs to produce IL-4, IL-10 and TGF-β. These cytokines drive the generation of so-called type 2 T helper cells (Th2 cells), which express IL-4, IL-5 and/or IL-13 [56, 57], and that stimulate antibody-mediated immunity and host defense against parasitic infections.

Visualization of T cell priming using T cells from TCR transgenic mice and two-photon microscopy of intact lymph nodes has revealed that the contacts between Agexpressing DC and Ag-specific T cells can be divided in three phases [58, 59]. During the first phase (from ~6–12 h after immunization) DC-T cell interactions are dynamic, ranging from 2 to 10 min, and T cells start to express early activation markers such as CD44 and CD69 [58, 59]. In the absence of Ag, the motility of the T cells and DC is extensive, enabling an individual DC to interact with an estimated 500-5000 T cells per hour [60, 61]. The contacts in the second phase (from ~12 to 20 h after immunization) are long-lasting (>1 h) and T cells reach maximum expression levels of activation markers and begin to produce effector cytokines such as IL-2 and IFN- $\gamma$  [58, 59]. Stable interactions are not observed in the absence of Ag [58]. In the third phase (1–2 days after immunization) T cell-APC interactions are dynamic again, which coincides with the onset of proliferation [58, 59]. Based on an estimate of the frequency of Ag-specific T cells before Ag encounter and the number of Ag-specific T cells present at the peak of an anti-LCMV specific CD8+ T cell response, the peak rate of division was calculated to be 6-8 h [19, 23]. More recent experiments using 5- and 6-carboxyfluorescein diacetate succinimidyl ester (CFSE), a fluorescent dye that binds to free amines of the cell and is equally divided amongst daughter cells, show that activated CD8<sup>+</sup> T cells have a division rate of 4–6 h  $[62, 63]$ , whereas activated CD4<sup>+</sup> T cells have an estimated division rate of 6–8 h [64]. This indicates that under optimal conditions a single T cell can give rise to an offspring of  $\sim$ 1,000 T cells in a 2-day period.

During proliferation, activated T cells progressively gain effector functions, and at the end of the expansion phase T cells express high levels of cytokines and in case of CD8+ T cells have acquired cytotoxic capacities [40–44]. Interestingly, it has been shown that a brief period of Ag stimulation (8–48 h) can be sufficient to commit CD8+ and CD4+ T cells to proliferate and differentiate independent of further antigenic stimulation [65–70]. This indicates that at least some of the properties of the progeny of a T cell are programmed before a T cell undergoes its first round of division. This autonomous program of differentiation may serve to allow APC to activate a higher number of Ag-specific T cells as compared with a situation in which T cells and their progeny would require prolonged APC contact.

In studies that simultaneously quantified Ag-specific  $CD4<sup>+</sup>$  and  $CD8<sup>+</sup>$  T cell responses in a single host, it was found that the kinetics of the Ag-specific CD4<sup>+</sup> and CD8<sup>+</sup>

T cell responses do not necessarily coincide. Whereas in the LCMV- and LM infection models Ag-specific CD4+ and CD8+ T cells were found to peak at the same time point [28, 31, 34], in other infections, such as MoMSV in mice and CMV and EBV in humans, the Ag-specific CD4+ T cell response was found to peak earlier [10, 32, 33]. These data suggest that depending on the pathogen, the kinetics of Ag-specific  $CD4^+$  and  $CD8^+$  T cell response may differ. It is currently unclear which properties of the pathogen determine the kinetics of Ag-specific CD4+ and CD8+ T cell responses. It seems quite possible that differences in the kinetics of MHC class I and II-restricted Ag presentation, depending for instance on viral tropism or the presence of free versus cell-associated pathogen, may be a causal factor, but any direct evidence for this is lacking.

## **Contraction**

During the contraction phase, the number of Ag-specific T cells declines by massive apoptosis to 5-10% of those at the peak of the response. The contraction phase may serve two goals. First, it may limit immunopathology either due to inadvertent cross-reactivity of the activated T cells with endogenous pMHC complexes, or in cases of high Ag load. Second, and perhaps more important, contraction of T cell responses may be required to preserve the ability to respond to other pathogens. In many experimental systems, the onset of CD8+ T cell contraction correlates with pathogen clearance, suggesting that Ag-specific CD8+ T cells 'sense' that the pathogen has been cleared. However, recent experiments using attenuated strains of LM or administration of antibiotics during LM infection show that the contraction kinetics are independent of the duration of infection, indicating that the decay in Ag-specific CD8+ T cell numbers is programmed before Ag load reduces [71]. Further experiments indicated that cell death during the contraction phase is controlled by inflammation and IFN- $\gamma$  levels early after infection [72], which may be due to a direct effect of IFN- $\gamma$  on CD8<sup>+</sup> T cells [73]. Although signals delivered early after infection may in part program the kinetics of T cell contraction in the following days, other studies have demonstrated that contraction of T cell responses is not entirely autonomous and extrinsic factors such as cytokines do contribute. For instance, the administration of IL-2 during the contraction phase has been shown to sustain the number of effector T cells [74]. In addition, costimulatory signals such as signals derived from CTLA-4, PD-1 and BTLA may further modulate the contraction of Ag-specific T cell responses [75–77]. In line with this idea, we recently showed that signals provided by CD70 may also influence the kinetics of contraction as in CD70Tg mice, in which the CD27 coreceptor is continuously triggered, contraction of the Ag-specific T cell pool is somewhat delayed [78]. Although it is unclear by which mechanisms cytokines and costimulatory molecules influence the contraction of Ag-specific T cell responses, alterations in the expression of the usual suspects of pro- and anti-apoptotic molecules seem a safe bet. Evidence for a role of pro-apoptotic molecules has been provided by the finding that the contraction phase of Ag-specific  $CD8<sup>+</sup> T$  cells is prolonged in mice lacking the Bcl-2 family member Bim [79].

#### **Memory phase**

After the contraction phase, Ag-specific T cells are maintained at levels that are greatly elevated compared with frequencies in naïve mice, and these remaining cells are termed memory T cells. In mice infected with LCMV or LM, Ag-specific CD4<sup>+</sup> memory T cell numbers were found to gradually decline, whereas Ag-specific CD8+ memory T cell numbers remained stable at ~5–10% of the T cell levels found during the peak of the response [28, 34]. The maintenance of memory T cell numbers is based on the balance between the low death rate amongst memory T cells, and production of new offspring by homeostatic proliferation of memory T cells. The homeostatic proliferation of both CD4<sup>+</sup> and CD8<sup>+</sup> memory T cells has been shown to occur in the absence of MHC molecules [80–85] and after ablation of TCR expression on memory T cells [86] and is thus considered Ag independent. Homeostatic proliferation of memory T cells is driven by cytokines such as IL-7 and IL-15 [87–93] and the difference in memory cell maintenance between CD4+ and CD8+ T cells may be explained by their distinct sensitivity to IL-7 and IL-15. Specifically, whereas IL-7 and IL-15 both contribute to CD8<sup>+</sup> T cell memory maintenance, IL-7 seems to play a more dominant role in the maintenance of CD4<sup>+</sup> T cell memory [87-93].

Although CD8<sup>+</sup> memory T cell numbers generally remain stable, heterologous infections have been found to impact on the stability of CD8<sup>+</sup> T cell memory. Memory T cells that do not cross-react with Ag that are present during the heterologous infection decline in number [94]. However, cross-reactivity of memory T cells with Ag from two different (un)related pathogens is not uncommon and can lead to increased CD8<sup>+</sup> memory T cell levels upon heterologous infection [94, 95].

Formation of T cell memory serves to mold the T cell repertoire towards Ags that have been encountered previously. Compared with primary T cell responses, secondary (memory) T cell responses are more rapid [45, 96], thereby resulting in faster pathogen clearance. The more rapid build-up of an army of effector cells is in large part due to the higher precursor frequency of memory T cells, but also due to a faster response upon TCR triggering, a shorter cycling time and increased survival of dividing memory T cells compared with naïve T cells [45, 96–98]. In addition to this numerical aspect, memory T cells are more rapidly capable of performing specific effector functions, such as cytolysis and cytokine secretion, upon TCR triggering [97, 98].

#### **Lineage relationships between naïve, effector and memory T cells**

It has long been debated whether memory T cells are derived from effector T cells or from naïve T cells that have not passed through an effector cell stage. Two recent studies argue that CD8<sup>+</sup> memory T cells are the progeny of effector T cells, but the debate may not be settled. In these studies, it was found that at the peak of the primary CD8+ T cell response, two subsets of cells can be identified that express different levels of the IL-7 receptor  $\alpha$ chain (CD127) [99, 100]. Of these cells, only the pool of T cells that express high levels of CD127 can give rise to long-lived memory cells [99, 100], and the majority of these CD127+ T cells were shown to have effector T cell properties, such as the capacity to kill and produce IFN- $\gamma$ [99]. These results argue in favor of a linear differentiation model in which naïve CD8+ T cells differentiate into memory T cells by passing through an effector stage. However, it remains possible that  $CD8<sup>+</sup>$  memory T cells develop from the minority of CD127+ cells that do not have effector T cell properties. Perhaps more important, these studies do not establish whether the capacity of a T cell to enter the memory T cell pool is instilled during early Ag encounter (e. g. by the quality of the APC), or is controlled at a later phase.

One study has provided evidence that expression of the CD8aa homodimer on effector T cells may also be used as a marker for CD8+ memory T cell precursors [101]. However, it is presently unclear how  $CD8\alpha\alpha$  expression is connected to T cell survival (as is the case for the memory precursor marker CD127), and this will require further study. A study by the group of R. Seder, in which CD4+ T cells were separated based on the capacity to produce IFN- $\gamma$ , indicated that IFN- $\gamma$ -producing CD4<sup>+</sup> T cells do not proliferate upon adoptive transfer, whereas IFN- $\gamma$ negative cells do [102]. At face value, these data argue that CD4<sup>+</sup> memory T cells are not derived from CD4<sup>+</sup> effector T cells. It is, however, unclear to what extent the in vitro peptide stimulation and method to isolate the  $IFN-\gamma$ -producing cells might have influenced the destiny of the cells.

#### **Role of CD4 help in CD8+ T cell responses**

Depending on the nature of the antigenic challenge, APC also require signals from CD4+ T cells to 'help' primary

CD8+ T cell responses. In settings in which the Ag is introduced in the absence of inflammatory mediators (e. g. soluble proteins and Ag-loaded cells), APCs are generally unable to efficiently prime naïve CD8<sup>+</sup> T cells without the help of CD4+ T cells. In these cases CD40 ligation on APCs has been shown to bypass this requirement for CD4+ T cell help, which led to the concept that CD40Lexpressing CD4+ T cells license CD40-expressing APCs (by upregulating costimulatory molecules and cytokines) to stimulate CD8+ T cells. In line with this concept, it has been demonstrated that CD4<sup>+</sup> and CD8<sup>+</sup> T cells need to recognize Ag on the same APCs [103, 104].

Experiments with live pathogens, such as LM or LCMV, showed that primary CD8<sup>+</sup> T cell responses do not necessarily depend on CD4<sup>+</sup> T cells [105–108]. This is likely to be due to the ligation of Toll-like receptors on APCs, thereby bypassing the requirement for CD4+ T cell help. Because T cell responses against certain other pathogens are CD4+ T cell dependent [109, 110], one may assume that these pathogens are intrinsically less potent in inducing inflammatory signals. Furthermore, while in one study in which a high dose of LM was used, CD4+ T cell help was found to be dispensable [107, 108], in a second study that used a lower dose of LM, the presence of CD4+ T cell help was essential [111]. These data suggest that the requirement for  $CD4^+$  T cell help may not only depend on the type of pathogen but may also be more profound at lower pathogen doses.

Although there is now solid evidence that CD4+ T cells can provide help to CD8<sup>+</sup> T cells via APC licensing, this does not necessarily invalidate the traditional model in which CD4<sup>+</sup> T cells directly 'help' CD8<sup>+</sup> T cells. Specifically, it has been suggested that  $CD4^+$  T cells provide help to  $CD8<sup>+</sup>$  T cells via secretion of IL-2. This model is largely based on the observations that IL-2 is a potent T cell growth factor in vitro and that activated CD4+ T cells produce copious amounts of IL-2. However, it remains to be elucidated whether CD4<sup>+</sup> T cell-derived IL-2 enhances CD8+ T cell responses in vivo. Help of CD4+ T cells to CD8+ T cells may conceivably also occur by direct cell-cell contact. For example, it has been reported that ligation of CD40 expressed on CD8+ T cells by CD40L expressed on CD4<sup>+</sup> T cells can boost CD8<sup>+</sup> T cell responses, although this is not observed in all model systems [104, 112, 113].

In both non-inflammatory and inflammatory conditions, memory  $CD8<sup>+</sup>$  T cell responses were found to be dependent on the presence of CD4+ T helper cells during the primary response. Whether these CD4<sup>+</sup> T cells are required to instill the capacity for secondary expansion in CD8+ T cells during the priming/expansion phase is not fully resolved. Work from four independent groups demonstrated that when CD4<sup>+</sup> T cells were depleted during priming, memory CD8+ T cells displayed an impaired secondary expansion, suggesting that the helper T cells somehow program CD8<sup>+</sup> T cells during acute infection, and that subsequent availability of help has no influence [104, 105, 107, 108]. However, a more recent study from the Bevan group indicates that CD4+ T cells are not required during but rather after the priming phase for the maintenance and optimal function of memory CD8+ T cells [114]. The discrepancy between these reports necessitates further investigation and might be explained by differences between the experimental setup. Notably, the latter study analyzes the role of CD4<sup>+</sup> T cell help using TCR transgenic CD8+ T cells rather than endogenous CD8+ T cells, and there are indications that under certain conditions the use of TCR transgenic cells may not be optimal (see further).

#### **Heterogeneity in effector T cell populations**

Ag-specific T cells are heterogeneous with respect to many different properties, such as the effector functions they can perform and the migration pattern that they display. The Th1/Th2 paradigm is one of the best examples of functional heterogeneity within the CD4<sup>+</sup>T cell pool. Th1 and Th2 T cell populations arise from the same uncommitted naïve CD4<sup>+</sup> T cell population. Recent evidence indicates that the nature of the pathogen encountered by an APC determines which Notch ligand is expressed by that APC, and that these Notch ligands are the initial factors that instruct Th1 and Th2 differentiation [115, 116]. Th2-promoting stimuli induce expression of the Notch ligand Jagged on APCs that triggers the Notch receptor on helper T cells and induces IL-4 transcription and expression of the transcription factor GATA-3 [115]. In contrast, the Notch ligand Delta (via a pathway that probably involves T-bet) provides a signal for helper T cells to develop into Th1 cells producing high amounts of IFN- $\gamma$  [115, 116]. The fate of T helper cells that have started to produce either IFN- $\gamma$  or IL-4 is then reinforced through a positive feedback loop. Specifically, triggering of the IFN- $\gamma$  receptor induces the expression of the transcription factor T-bet that further drives Th1 differentiation by increasing the accessibility and transcription of the *Ifng* locus. Vice versa, triggering of the IL-4 receptor induces the expression of the transcription factor GATA-3, which further drives Th2 differentiation by increasing the accessibility and transcription of the *Il4* locus. In addition, T-bet and GATA-3 are believed to induce the binding of repressive factors to the opposing locus (reviewed in [117, 118]). Collectively, these studies are providing a detailed picture of how the initial 'sensing' of the pathogen by APCs determines the activity of CD4+ T cells. It seems likely that similar mechanisms control aspects such as the homing potential of helper and cytotoxic T cells (see below), but there the details are still sketchy. Furthermore, in addition to the polarizing role of APCs, other cell types of the innate immune system, such as NK cells, are also likely to influence the functional characteristics of T helper cell responses by producing polarizing cytokines [119].

#### **Heterogeneity in homing potential of effector T cells**

The presence of pathogen at a peripheral site should not only yield an army of pathogen-specific T cells, but should preferably also provide cues to guide these cells to the site of pathogen invasion. A general mechanism that promotes accumulation of activated T cells at inflamed sites is formed by the inflammation-induced expression of extravasation-promoting signals on endothelial cells, such as chemokines and ligands for adhesion molecules. Whereas adhesion molecules initiate the first contact between T cells and the endothelium, the subsequent binding of T cells to chemokines is believed to initiate a process that allows the actual extravasation of T cells [120]. The molecules involved in this migration step can be distinct for different tissue sites. For instance, the  $\alpha$ 4 $\beta$ 7 integrin and chemokine receptor CCR9 guide lymphocytes to the lamina propria of the small intestine and the mucosal epithelium [121–123], whereas E-selectin ligands (E-lig) and P-selectin ligands (P-lig) guide T cells to inflamed skin (fig. 3)  $[124, 125]$ .

But how is the expression of these chemokine receptors and adhesion molecules on T cells regulated? Initial reports showed that the route of Ag entry determines which tissue-specific homing molecules are expressed by T cells [126, 127]. Subsequent studies demonstrated that T cells that were activated in vitro by DC from gutdraining lymph node (DLN) or skin DLN express chemokine receptors/adhesion molecules associated with gut and skin homing, respectively, and preferentially migrate to the corresponding effector site [128–130]. The notion that the Ag-presenting DC rather than the DLN in which Ag encounter takes place is responsible for the programming of homing potential receives further support from a recent study by Calzascia et al. [131]. This study demonstrates that T cells activated within the same DLN, but by DCs that drain from two different peripheral sites obtain distinct chemokine receptor/ integrin expression profiles that correlate with the site of Ag entry [131]. In line with these findings, Iwata et al. recently reported that retinoic acid, a factor that is uniquely produced by intestinal DC, imprints gut-tropism into T cells (fig.  $3$ ) [132].

If programming plays an important role in determining the in vivo migration of Ag-specific T cells, one would predict that T cells found at different effector sites would be the progeny of distinct naïve T cells. What is the evidence for this? The group of Pamer showed that the TCR  $V\beta$  repertoire of H2-K<sup>b</sup>-restricted LM-specific T cells



Figure 3. DC-induced acquisition of gut/skin-homing molecules during T cell activation. Retinoic acid produced by gut DCs induces expression of gut-homing molecules CCR9 and  $\alpha$ 4 $\beta$ 7 integrin on T cells. Skin DCs, via unknown mechanisms, mediate upregulation of skin-homing molecules E- and P-selectin ligands on T cells.

in the spleen and intestinal mucosa of mice are distinct [133]. This observation is consistent with the possibility that DCs involved in primary T cell activation may program these T cells and their progeny to accumulate at either site. However, the evidence is obviously indirect. Furthermore, two other recent studies observed no significant differences in the TCR  $V\beta$  repertoire of influenza virus- and LCMV-specific CD8<sup>+</sup> T cells that were isolated from different lymphoid organs and nonlymphoid organs (liver, lung and peritoneum) [134, 135], suggesting that individual T cells can generate progeny that migrate to different sites (but see note below). The observation that T cells that appear to be the progeny of the same cell can migrate to different sites may be due to the fact that in contrast to gut tropism, liver, lung and peritoneum tropism may not be imprinted in T cells. Alternatively, recent in vitro evidence suggests that the migration properties of T cells can also be reprogrammed upon incubation with DCs derived from DLN of the opposing tissue [128, 130].

Finally, it should be noted that it is far from clear whether TCR- $\beta$  chain sequencing can reliably tell whether effector T cells present at distinct sites are derived from the same naïve T cell. Thymocytes undergo a substantial proliferative burst following TCR-β chain recombination, and of the few Ag-specific T cells within the naïve T cell repertoire of a single mouse, a substantial number will have the same  $\beta$  chain. Thus, a similarity in  $TCR-\beta$  chain sequences of different  $T$  cell populations may simply be a reflection of the preponderance of that  $TCR-\beta$  chain in the naïve Ag-specific T cell repertoire and better techniques of tracing kinship in T cell populations will be required to elucidate these types of issues.



Figure 4. A model for immune-protection by central and effector memory T cells. Upon re-encounter of a pathogen, memory T cells in the periphery (effector memory T cells,  $T_{EM}$ ) may function as a first line of defense by performing immediate effector functions upon Ag encounter. Should they become overwhelmed by pathogen, backup is provided by memory T cells in lymphoid tissues (central memory  $\overline{T}$  cells,  $T_{CM}$ ), which expand upon Ag encounter and differentiate into effector T cells.

## **Heterogeneity in effector function/homing potential of memory T cells**

Based on the analysis of CD4<sup>+</sup> memory T cells isolated from human blood, Sallusto et al. proposed a concept in which two types of memory T cells, central and effector memory T cells, would co-exist. In this model (fig. 4), central memory T cells  $(T_{CM})$  were defined as resting memory T cells that express CCR7 and CD62L (two molecules that are both involved in the homing of T cells to lymphoid organs) [136, 137], and that produce IL-2 and low levels of IFN- $\gamma$ . Effector memory T cells (T<sub>EM</sub>) were defined by lack of CCR7 and CD62L, residence in peripheral tissues and secretion of high levels of IFN- $\gamma$ and low levels of IL-2 [138]. In this model, it was suggested that  $T_{EM}$  cells function as a first line of defense at mucosal sites, whereas  $T_{CM}$  cells are the back-up troops that have the capacity to proliferate and differentiate rapidly into effector cells upon renewed Ag encounter.

This model has a very clear appeal and since it was first proposed, many studies have analyzed the char-

acteristics of both CD4<sup>+</sup> and CD8<sup>+</sup> 'T<sub>CM</sub>' and 'T<sub>EM</sub>' cells, which were distinguished based on differences in expression of the lymph node homing receptors CCR7 or CD62L [17, 139–142]. Before delving further into the concept of distinct memory T cell subsets, it is important to note that data from several studies suggest that the use of phenotypic markers, such as CCR7 and CD62L, to define T cells that have different migration capacities has some limitations. Although it was suggested that CCR7+ T cells are not likely to migrate to peripheral organs, studies in mice and humans showed that a substantial fraction of tissue-infiltrating lymphocytes do express CCR7 [140, 143]. In addition, a fraction of T cells in human lymph nodes appear to be negative for CCR7 [143], which may be explained by the fact that T cells with low to non-detectable levels of CCR7 are still able to migrate to CCR7 ligands in a CCR7-dependent fashion [144]. Furthermore, the expression of both CCR7 and CD62L was found to be dynamic rather than static. Expression of both molecules is transiently upregulated upon activation, followed by a gradual decline [145, 146], and CD62L expression is reduced upon ligand encounter, due to shedding [147, 148]. Together, these data indicate that studying  $T_{CM}$ and  $T_{EM}$  subsets based on phenotypic markers does not equal the analysis of  $T_{CM}$  and  $T_{EM}$  subsets as based on location. Furthermore, because  $T_{CM}$  and  $T_{EM}$  cells have been proposed as T cell subsets with a role at distinct sites, isolation of the two subsets based on location may be more appropriate.

Going back to the data, what is the evidence for the  $T_{CM}/$ T<sub>EM</sub> concept? *Leishmania major*-specific central memory CD4<sup>+</sup> T cells and ovalbumin-specific central memory CD4<sup>+</sup> T cells, defined based on CD62L expression and localization, respectively, produce high levels of IL-2 and low levels of IFN-γ, whereas their effector memory T cell counterparts express high levels of IFN- $\gamma$  and low levels of IL-2 [142, 149]. In contrast, Unsoeld et al. found that LCMV-specific TCR transgenic CD4<sup>+</sup> central and effector memory T cells that were defined based on CCR7 expression show no difference in IFN- $\gamma$  production [140]. These discrepancies might be due to differences between different pathogens or might depend on the experimental setup. Although for CD4+ T cells the different memory T cell subsets were found to differ in their capacity to produce IL-2 and IFN- $\gamma$  in at least some studies, for CD8<sup>+</sup> T cells no clear differences in IFN-g production have been found between  $T_{CM}$  and  $T_{EM}$  cells [17, 140, 141, 150]. Only one study described that more IL-2 is produced in central as compared with effector memory CD8+ T cells [141]. Data of Masopust et al. indicate that central and peripheral CD8+ memory T cell subsets may differ in cytotoxic capacity. Specifically, vesicular stomatitis virus (VSV) and LM-specific CD8<sup>+</sup> memory T cells isolated from peripheral organs were found to have increased cytotoxic function compared with their splenic counterparts [150]. However,  $CD8^+$  T<sub>EM</sub> cells isolated from the lung of RSV, Sendai or influenza virus-infected mice exert no cytotoxicity directly ex vivo [151, 152]. In addition, there is controversy about the properties of memory CD8<sup>+</sup> T cell subsets in the LCMV model. A study by Wolint et al. showed that CD62L<sup>-</sup> LCMV-specific memory CD8<sup>+</sup> T cells have increased cytotoxic capacity compared with CD62L+ CD8+ memory T cells [17]. In contrast, two other studies found no difference in cytotoxic capacity between LCMV-specific central memory and effector memory CD8+ T cells that were defined based on either CCR7 or CD62L expression [140, 141]. These discrepancies might again be due to differences in experimental setup. For instance, the latter two studies analyzed the properties of transferred TCR transgenic T cells rather than those of endogenous T cells.

One of the most important questions raised by the existence of different Ag-specific memory T cell subsets is their importance in protecting a host upon re-encounter of a pathogen. Zaph et al. found that *Leishmania major*-specific CD62L<sup>-</sup> CD4<sup>+</sup>  $T_{EM}$  cells are able to reduce pathogen load upon secondary *Leishmania major* infection within 3 weeks of infection, whereas a reduction in pathogen load by  $CD62L^+CD4^+T_{CM}$  cells required 6 weeks [142]. This would be consistent with the proposed concept that  $T_{EM}$  cells can function as a first line of defense and  $T_{CM}$ cells are the back-up troops. However, many other explanations are possible as well.

The data regarding the capacity of  $CD8<sup>+</sup>$  T<sub>EM</sub> and T<sub>CM</sub> cells to protect a host upon secondary infection look quite different. Wherry et al. showed that spleen-derived CD62L<sup>+</sup> CD8<sup>+</sup> memory T cells, but not CD62L<sup>-</sup> and lung-derived (70% CD62L low) CD8+ memory T cells could protect naïve mice upon challenge with vaccinia virus, suggesting that  $CD8^+$  T<sub>CM</sub> cells are more important to protect mice from re-infection than  $T_{EM}$  cells [141]. Wherry et al. argued that this difference is likely due to the fact that  $CDS^+$   $T_{EM}$  cells have a decreased proliferative potential as compared to  $CD8^+$  T<sub>CM</sub> cells. However, this finding does not necessarily exclude a role for CD8+  $T<sub>EM</sub>$  cells as a first line of defense. Depending on the pathogen load at a peripheral site early after infection, the different T cell subsets may alter the course of infection. Specifically, if large amounts of pathogen enter the host, locally residing  $T_{EM}$  cells that have a limited capacity to expand are likely to be insufficient. If, however, the local pathogen load is initially low, memory T cell populations that have the ability to rapidly kill the invading pathogen could make a lasting impression. Based on this argument it may be reasoned that most experimental systems in which the role of  $T_{EM}$  and  $T_{CM}$  cells are studied tend to underestimate the contribution of  $T_{EM}$  cells, because the amounts of pathogen that are introduced are likely to be higher than in most naturally occurring infections.

## **Lineage relationship between different memory T cell subsets**

The idea that under certain conditions a particular memory T cell subset or combination of subsets would be best in mediating protection against a certain pathogen also raises the question how these T cell subsets develop and how they are maintained. Based on in vitro experiments a 'progressive differentiation model' was proposed, which suggests that depending on the strength and duration of the stimulus received by a naïve T cell, these cells will either fully differentiate into effector T cells that will then become  $T_{EM}$  cells, or arrest at an intermediate differentiation state and become  $T_{CM}$  cells [153]. Based on the finding that IL-7 and IL-15 induce differentiation of  $T_{CM}$  into  $T_{EM}$  in vitro [154, 155], it was suggested that a proportion of  $T_{CM}$  might subsequently differentiate into  $T_{EM}$  to replenish the effector memory pool without the requirement for Ag [153].

In contrast to the proposed differentiation of  $T_{CM}$  cells into  $T_{EM}$  cells, Wherry et al. showed that  $T_{CM}$  cells, as defined by CD62L expression, differentiate into  $T_{EM}$  in the presence of Ag, but not under homeostatic conditions [141].  $CD8<sup>+</sup> CD62L<sup>-</sup> T<sub>EM</sub> cells, on the other hand, were found$ to regain the expression of CD62L<sup>+</sup> in an Ag-independent fashion over a time period of 6–10 weeks, which made the authors conclude that naïve T cells might progressively differentiate following a linear, naïve -> effector cells ->  $T_{EM}$  cells ->  $T_{CM}$  cells, pathway [141]. However, a study by Bouneaud et al. recently showed that  $T_{EM}$  cells that have regained CD62L expression behave like  $T_{EM}$  cells rather than  $T_{CM}$  cells in that they are unable to mount a proliferative response upon a secondary challenge, indicating that acquisition of one of the characteristics of  $T_{CM}$ cells is not necessarily coupled to acquisition of other  $T_{CM}$ characteristics [139]. In addition, a recent paper by the group of Lefrancois shows that depending on the number of transferred TCR transgenic T cells,  $CD8^+$  T<sub>EM</sub> cells either do or do not develop into T cells with a  $T_{CM}$  phenotype [156]. Specifically, when only low numbers of TCR transgenic T cells were transferred,  $T_{EM}$  cells maintained their low CD62L phenotype, suggesting that  $T_{EM}$  cells do not differentiate into  $T_{CM}$  under physiological conditions. On a more general note, this latter study stresses that results obtained using transfer of high numbers of TCR transgenic T cells should be interpreted with caution.

A study by Klonowsky et al. that analyzed the migration patterns of CD8+ memory T cells using parabiotic mice showed that CD8<sup>+</sup> memory T cells in peripheral tissue as well as in lymphoid organs originate from blood-borne CD8+ memory T cells that continuously seed tissues after contraction of the immune response [157]. As the origin of the blood-borne CD8+ T cells remains unclear, these data may be explained by three different models. First, memory T cells might form one large pool of T cells in which individual cells continuously change their migration properties and localization, perhaps as a consequence of environmental signals. Second, these data might be interpreted as evidence for a blood-borne/lymphoid pool of memory T cells (for instance the memory T cell pool in the bone marrow [158]) that continuously gives rise to T cells that seed peripheral tissues. Third, the memory T cell pool might consist of several smaller pools of T cells that travel back and forth from the blood into the tissue, of which each pool has its specific tissue tropism.

#### **Conclusions and future perspectives**

The introduction of techniques to visualize Ag-specific T cells at the single cell level has dramatically improved our understanding of the regulation of Ag-specific CD4+ and CD8+ T cell responses during acute infections. Although  $CD4^+$  and  $CD8^+$  T cell responses go through the same phases of expansion, contraction and memory maintenance, Ag-specific CD4<sup>+</sup> T cell responses are generally much smaller in size than Ag-specific CD8+ T cell responses. Additional differences between CD4<sup>+</sup> and CD8+ T cell responses have been reported, such as differences in kinetics and memory maintenance. However, these differences are not observed in all infection models, indicating that they are unlikely to be due to intrinsic differences between CD4<sup>+</sup> and CD8<sup>+</sup> T cells, but rather depend on the type and amount of pathogen used. This is analogous to findings on the role of CD4+ T cell help in primary CD8+ T cell responses, where also the infectious agent, and more specifically the inflammatory milieu that the infectious agent creates, determines whether the primary CD8+ T cell response depends on CD4+ T cell help or not.

Clearly not only the Ag-specific interaction but also additional pathogen-derived cues are involved in shaping the ensuing T cell response. Rather than directly receiving signals via pathogens, T cells receive most of their signals via APCs in the form of Ag presented in MHC molecules, costimulatory molecules and cytokines. Interestingly, a brief interaction of a T cell with a stimulating APC not only determines the short-term action of that particular T cell, but also instructs what will happen to its progeny. This includes its capacity to proliferate and differentiate into effector cells, its ability to react to certain chemokines and possibly also its survival into the memory T cell pool. This type of fate determination may be based on mechanisms similar to those driving the development of the Th1 and Th2 subsets, where polarization was found to be dependent on a cytokine feed-back loop that promotes the differential expression of transcription factors and progressive changes in chromatin structure. For instance, the finding that precursors of CD8<sup>+</sup> memory T cells express the IL-7 receptor, which is involved in

regulating homeostatic proliferation of memory T cells, suggests that triggering of this receptor might drive the differentiation of these cells. However, many of the molecular mechanisms that underlie the programming of the expansion, differentiation, migration and memory formation of T cells remain to be elucidated. The existence of different subsets within the  $CD4^+$  and  $CD8^+$  T cell pool raises the question how these subsets are related. Although adoptive transfer of different T cell subsets has been used to provide some answers, many questions remain open. Rather than studying the fate of a pool of (supposedly) homogenous adoptively transferred T cells, one ideally would like to track the progeny of individual T cells. For this purpose, we are developing a novel approach in which individual T cells are tagged with a genetic barcode using retroviral transduction. This tagging of individual cells with unique identifiers coupled to a microarray-based detection system may conceivably be used to further improve our understanding of the family relationships between distinct cell populations.

The insights gained on the development of Ag-specific  $CD4<sup>+</sup>$  and  $CD8<sup>+</sup>$  T cell responses upon acute infection should be valuable for the improvement of vaccination strategies. Studies from the past years have taught us how many Ag-specific T cells we have and what they look like. In future experiments, we should focus on which subsets of Ag-specific T cells we need to control a given pathogen, and how we can best generate this subset by vaccination.

*Acknowledgements***.** We would like to thank Jannie Borst, Anna Keller and Jeroen van Heijst for useful discussions. Work in the authors' laboratory is supported by ZON-MW grants 431-00-005, 900-00-03 and Dutch Cancer Society grants NKI2001-2419, NKI 2001-2563 and NKI 2003-2860.

- 1 Altman J. D., Moss P. A., Goulder P. J., Barouch D. H., McHeyzer-Williams M. G., Bell J. I. et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science **274:** 94– 96
- 2 Bakker A. H. and Schumacher T. N. (2005) MHC multimer technology: current status and future prospects. Curr. Opin. Immunol. **17:** 428–433
- 3 Davis M. M., Boniface J. J., Reich Z., Lyons D., Hampl J., Arden B. et al. (1998) Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol. **16:** 523–544
- 4 Haanen J. B., van Oijen M. G., Tirion F., Oomen L. C., Kruisbeek A. M., Vyth-Dreese F. A. et al. (2000) In situ detection of virus- and tumor-specific T-cell immunity. Nat. Med. **6:** 1056–1060
- 5 Soen Y., Chen D. S., Kraft D. L., Davis M. M. and Brown P. O. (2003) Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol. **1:** E65
- Stone J. D., Demkowicz W. E., Jr. and Stern L. J. (2005) HLArestricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays. Proc. Natl. Acad. Sci. USA **102:** 3744–3749
- 7 Kozono H., White J., Clements J., Marrack P. and Kappler J. (1994) Production of soluble MHC class II proteins with covalently bound single peptides. Nature **369:** 151–154
- 8 Crawford F., Kozono H., White J., Marrack P. and Kappler J. (1998) Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity **8:** 675–682
- 9 Ressing M. E., van Leeuwen D., Verreck F. A., Gomez R., Heemskerk B., Toebes M. et al. (2003) Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc. Natl. Acad. Sci. USA **100:** 11583–11588
- 10 Schepers K., Toebes M., Sotthewes G., Vyth-Dreese F. A., Dellemijn T. A., Melief C. J. et al. (2002) Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J. Immunol. **169:** 3191–3199
- 11 Day C. L., Seth N. P., Lucas M., Appel H., Gauthier L., Lauer G. M. et al. (2003) Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J. Clin. Invest. **112:** 831–842
- 12 Novak E. J., Liu A. W., Nepom G. T. and Kwok W. W. (1999) MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. **104:** R63–R67
- 13 Lucas M., Day C. L., Wyer J. R., Cunliffe S. L., Loughry A., McMichael A. J. et al. (2004) Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J. Virol. **78:** 7284–7287
- 14 Liu F. and Whitton J. L. (2005) Cutting edge: re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections. J. Immunol. **174:** 5936–5940
- 15 Manz R., Assenmacher M., Pfluger E., Miltenyi S. and Radbruch A. (1995) Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc. Natl. Acad. Sci. USA **92:** 1921–1925
- 16 Betts M. R., Brenchley J. M., Price D. A., De Rosa S. C., Douek D. C., Roederer M. et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods **281:** 65–78
- 17 Wolint P., Betts M. R., Koup R. A. and Oxenius A. (2004) Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J. Exp. Med. **199:** 925–936
- 18 Kostense S., Ogg G. S., Manting E. H., Gillespie G., Joling J., Vandenberghe K. et al. (2001) High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur. J. Immunol. **31:** 677–686
- 19 Butz E. A. and Bevan M. J. (1998) Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity **8:** 167–175
- 20 Callan M. F., Tan L., Annels N., Ogg G. S., Wilson J. D., O'Callaghan C. A. et al. (1998) Direct visualization of antigenspecific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. **187:** 1395–1402
- 21 Flynn K. J., Belz G. T., Altman J. D., Ahmed R., Woodland D. L. and Doherty P. C. (1998) Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity **8:** 683–691
- 22 Gallimore A., Glithero A., Godkin A., Tissot A. C., Pluckthun A., Elliott T. et al. (1998) Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. **187:** 1383–1393
- 23 Murali-Krishna K., Altman J. D., Suresh M., Sourdive D. J., Zajac A. J., Miller J. D. et al. (1998) Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity **8:** 177–187
- 24 Kotzin B. L., Falta M. T., Crawford F., Rosloniec E. F., Bill J., Marrack P. et al. (2000) Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA **97:** 291–296
- 25 Meyer A. L., Trollmo C., Crawford F., Marrack P., Steere A. C., Huber B. T. et al. (2000) Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc. Natl. Acad. Sci. USA **97:** 11433–11438
- 26 Liu C. P., Jiang K., Wu C. H., Lee W. H. and Lin W. J. (2000) Detection of glutamic acid decarboxylase-activated T cells with I-Ag7 tetramers. Proc. Natl. Acad. Sci. USA **97:** 14596–14601
- 27 Rees W., Bender J., Teague T. K., Kedl R. M., Crawford F., Marrack P. et al. (1999) An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. USA **96:** 9781–9786
- 28 Homann D., Teyton L. and Oldstone M. B. (2001) Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat. Med. **7:** 913–919
- 29 Kuroda M. J., Schmitz J. E., Lekutis C., Nickerson C. E., Lifton M. A., Franchini G. et al. (2000) Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer. J. Virol. **74:** 8751–8756
- 30 Kwok W. W., Liu A. W., Novak E. J., Gebe J. A., Ettinger R. A., Nepom G. T. et al. (2000) HLA-DQ tetramers identify epitopespecific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J. Immunol. **164:** 4244–4249
- 31 Whitmire J. K., Murali-Krishna K., Altman J. and Ahmed R. (2000) Antiviral CD4 and CD8 T-cell memory: differences in the size of the response and activation requirements. Philos. Trans. R. Soc. Lond. B Biol. Sci. **355:** 373–379
- 32 Gamadia L. E., Remmerswaal E. B., Weel J. F., Bemelman F., van Lier R. A. and Ten Berge I. J. (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood **101:** 2686–2692
- 33 Precopio M. L., Sullivan J. L., Willard C., Somasundaran M. and Luzuriaga K. (2003) Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J. Immunol. **170:** 2590–2598
- 34 Schiemann M., Busch V., Linkemann K., Huster K. M. and Busch D. H. (2003) Differences in maintenance of CD8+ and CD4+ bacteria-specific effector-memory T cell populations. Eur. J. Immunol. **33:** 2875–2885
- 35 Foulds K. E., Zenewicz L. A., Shedlock D. J., Jiang J., Troy A. E. and Shen H. (2002) Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. **168:** 1528–1532
- 36 Grufman P., Wolpert E. Z., Sandberg J. K. and Karre K. (1999) T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur. J. Immunol. **29:** 2197–2204
- 37 Kedl R. M., Schaefer B. C., Kappler J. W. and Marrack P. (2002) T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat. Immunol. **3:** 27–32
- 38 Probst H. C., Dumrese T. and van den Broek M. F. (2002) Cutting edge: competition for APC by CTLs of different specificities is not functionally important during induction of antiviral responses. J. Immunol. **168:** 5387–5391
- 39 Creusot R. J., Thomsen L. L., Tite J. P. and Chain B. M. (2003) Local cooperation dominates over competition between CD4+ T cells of different antigen/MHC specificity. J. Immunol. **171:** 240–246
- 40 Fazekas de St Groth B., Smith A. L., Koh W. P., Girgis L., Cook M. C. and Bertolino P. (1999) Carboxyfluorescein diacetate succinimidyl ester and the virgin lymphocyte: a marriage made in heaven. Immunol. Cell Biol. **77:** 530–538
- 41 Gett A. V. and Hodgkin P. D. (1998) Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation. Proc. Natl. Acad. Sci. USA **95:** 9488–9493
- 42 Gudmundsdottir H., Wells A. D. and Turka L. A. (1999) Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J. Immunol. **162:** 5212–5223
- 43 Oehen S. and Brduscha-Riem K. (1998) Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J. Immunol. **161:** 5338–5346
- 44 Opferman J. T., Ober B. T. and Ashton-Rickardt P. G. (1999) Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science **283:** 1745–1748
- 45 Ahmed R. and Gray D. (1996) Immunol ogical memory and protective immunity: understanding their relation. Science **272:** 54–60
- 46 Sprent J. and Tough D. F. (2001) T cell death and memory. Science **293:** 245–248
- 47 Guermonprez P., Valladeau J., Zitvogel L., Thery C. and Amigorena S. (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. **20:** 621–667
- 48 Kapsenberg M. L. (2003) Dendritic-cell control of pathogendriven T-cell polarization. Nat. Rev. Immunol.. **3:** 984–993
- 49 Reis e Sousa C. (2004) Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. **16:** 21–25
- 50 Matzinger P. (2002) The danger model: a renewed sense of self. Science **296:** 301–305
- 51 Shi Y., Evans J. E. and Rock K. L. (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature **425:** 516–521
- 52 Croft M. (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. **3:** 609–620
- 53 Lindstein T., June C. H., Ledbetter J. A., Stella G. and Thompson C. B. (1989) Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science **244:** 339–343
- 54 Hutloff A., Dittrich A. M., Beier K. C., Eljaschewitsch B., Kraft R., Anagnostopoulos I. et al. (1999) ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature **397:** 263–266
- 55 Heath W. R. and Carbone F. R. (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. **19:** 47–64
- 56 Carter L. L. and Dutton R. W. (1996) Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr. Opin. Immunol. **8:** 336–342
- 57 Mosmann T. R. and Sad S. (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today **17:** 138–146
- 58 Hugues S., Fetler L., Bonifaz L., Helft J., Amblard F. and Amigorena S. (2004) Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat. Immunol. **5:** 1235–1242
- Mempel T. R., Henrickson S. E. and Von Andrian U. H. (2004) T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature **427:** 154–159
- 60 Bousso P. and Robey E. (2003) Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. **4:** 579–585
- 61 Miller M. J., Hejazi A. S., Wei S. H., Cahalan M. D. and Parker I. (2004) T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc. Natl. Acad. Sci. USA **101:** 998–1003
- 62 Kurts C., Kosaka H., Carbone F. R., Miller J. F. and Heath W. R. (1997) Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J. Exp. Med. **186:** 239–245
- 63 van Stipdonk M. J., Lemmens E. E. and Schoenberger S. P. (2001) Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol. **2:** 423–429
- 64 Jelley-Gibbs D. M., Lepak N. M., Yen M. and Swain S. L. (2000) Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation. J. Immunol. **165:** 5017–5026
- 65 Hafalla J. C., Sano G., Carvalho L. H., Morrot A. and Zavala F. (2002) Short-term antigen presentation and single clonal burst limit the magnitude of the CD8(+) T cell responses to malaria liver stages. Proc. Natl. Acad. Sci. USA **99:** 11819–11824
- 66 Iezzi G., Karjalainen K. and Lanzavecchia A. (1998) The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity **8:** 89–95
- Kaech S. M. and Ahmed R. (2001) Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. **2:** 415–422
- 68 Lee W. T., Pasos G., Cecchini L. and Mittler J. N. (2002) Continued antigen stimulation is not required during CD4(+) T cell clonal expansion. J. Immunol. **168:** 1682–1689
- 69 Mercado R., Vijh S., Allen S. E., Kerksiek K., Pilip I. M. and Pamer E. G. (2000) Early programming of T cell populations responding to bacterial infection. J. Immunol. **165:** 6833–6839
- van Stipdonk M. J., Hardenberg G., Bijker M. S., Lemmens E. E. Droin N. M., Green D. R. et al. (2003) Dynamic programming of CD8+ T lymphocyte responses. Nat. Immunol. **4:** 361–365
- 71 Badovinac V. P., Porter B. B. and Harty J. T. (2002) Programmed contraction of CD8(+) T cells after infection. Nat. Immunol. **3:** 619–626
- 72 Badovinac V. P., Porter B. B. and Harty J. T. (2004) CD8+ T cell contraction is controlled by early inflammation. Nat. Immunol. **5:** 809–817
- Whitmire J. K., Tan J. T. and Whitton J. L. (2005) Interferon-{gamma} acts directly on CD8+ T cells to increase their abundance during virus infection. J. Exp. Med. **201:** 1053–1059
- 74 Blattman J. N., Grayson J. M., Wherry E. J., Kaech S. M., Smith K. A. and Ahmed R. (2003) Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. **9:** 540–547
- Greenwald R. J., Freeman G. J. and Sharpe A. H. (2005) The B7 family revisited. Annu. Rev. Immunol. **23:** 515–548
- 76 Pandiyan P., Gartner D., Soezeri O., Radbruch A., Schulze-Osthoff K. and Brunner-Weinzierl M. C. (2004) CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J. Exp. Med. **199:** 831–842
- 77 Riley J. L. and June C. H. (2005) The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood **105:** 13–21
- 78 Arens R., Schepers K., Nolte M. A., van Oosterwijk M. F., van Lier R. A., Schumacher T. N. et al. (2004) Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J. Exp. Med. **199:** 1595–1605
- 79 Pellegrini M., Belz G., Bouillet P. and Strasser A. (2003) Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim. Proc. Natl. Acad. Sci. USA **100:** 14175–14180
- Kassiotis G., Garcia S., Simpson E. and Stockinger B. (2002) Impairment of Immunol ogical memory in the absence of MHC despite survival of memory T cells. Nat. Immunol. **3:** 244–250
- 81 Lau L. L., Jamieson B. D., Somasundaram T. and Ahmed R. (1994) Cytotoxic T-cell memory without antigen. Nature **369:** 648–652
- 82 Murali-Krishna K., Lau L. L., Sambhara S., Lemonnier F., Altman J. and Ahmed R. (1999) Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 286: 1377-1381
- 83 Swain S. L., Hu H. and Huston G. (1999) Class II-independent generation of CD4 memory T cells from effectors. Science **286:** 1381–1383
- Tan J. T., Ernst B., Kieper W. C., LeRoy E., Sprent J. and Surh C. D. (2002) Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. **195:** 1523–1532
- 85 Tanchot C., Lemonnier F. A., Perarnau B., Freitas A. A. and Rocha B. (1997) Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science **276:** 2057–2062
- Polic B., Kunkel D., Scheffold A. and Rajewsky K. (2001) How alpha beta T cells deal with induced TCR alpha ablation. Proc. Natl. Acad. Sci. USA **98:** 8744–8749
- 87 Becker T. C., Wherry E. J., Boone D., Murali-Krishna K., Antia R., Ma A. et al. (2002) Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J. Exp. Med. **195:** 1541–1548
- 88 Goldrath A. W., Sivakumar P. V., Glaccum M., Kennedy M. K., Bevan M. J., Benoist C. et al. (2002) Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J. Exp. Med. **195:** 1515–1522
- 89 Kondrack R. M., Harbertson J., Tan J. T., McBreen M. E., Surh C. D. and Bradley L. M. (2003) Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. **198:** 1797–1806
- Lenz D. C., Kurz S. K., Lemmens E., Schoenberger S. P., Sprent J., Oldstone M. B. et al. (2004) IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc. Natl. Acad. Sci. USA **101:** 9357–9362
- 91 Li J., Huston G. and Swain S. L. (2003) IL-7 promotes the transition of CD4 effectors to persistent memory cells. J. Exp. Med. **198:** 1807–1815
- 92 Schluns K. S., Kieper W. C., Jameson S. C. and Lefrancois L. (2000) Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. **1:** 426–432
- 93 Schluns K. S., Williams K., Ma A., Zheng X. X. and Lefrancois L. (2002) Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J. Immunol. **168:** 4827–4831
- 94 Welsh R. M., Selin L. K. and Szomolanyi-Tsuda E. (2004) Immunol ogical memory to viral infections. Annu. Rev. Immunol. **22:** 711–743
- 95 Kim S. K. and Welsh R. M. (2004) Comprehensive early and lasting loss of memory CD8 T cells and functional memory during acute and persistent viral infections. J. Immunol. **172:** 3139–3150
- 96 Kaech S. M., Wherry E. J. and Ahmed R. (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. **2:** 251–262
- 97 Bachmann M. F., Barner M., Viola A. and Kopf M. (1999) Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur. J. Immunol. **29:** 291–299
- 98 Veiga-Fernandes H., Walter U., Bourgeois C., McLean A. and Rocha B. (2000) Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat. Immunol. **1:** 47–53
- 99 Huster K. M., Busch V., Schiemann M., Linkemann K., Kerksiek K. M., Wagner H. et al. (2004) Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc. Natl. Acad. Sci. USA **101:** 5610–5615
- 100 Kaech S. M., Tan J. T., Wherry E. J., Konieczny B. T., Surh C. D. and Ahmed R. (2003) Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. **4:** 1191–1198
- 101 Madakamutil L. T., Christen U., Lena C. J., Wang-Zhu Y., Attinger A., Sundarrajan M. et al. (2004) CD8alphaalphamediated survival and differentiation of CD8 memory T cell precursors. Science **304:** 590–593
- 102 Wu C. Y., Kirman J. R., Rotte M. J., Davey D. F., Perfetto S. P., Rhee E. G. et al. (2002) Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. **3:** 852–858
- 103 Bennett S. R., Carbone F. R., Karamalis F., Miller J. F. and Heath W. R. (1997) Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. **186:** 65–70
- 104 Bourgeois C., Rocha B. and Tanchot C. (2002) A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science **297:** 2060–2063
- 105 Janssen E. M., Lemmens E. E., Wolfe T., Christen U., von Herrath M. G. and Schoenberger S. P. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature **421:** 852–856
- 106 Rahemtulla A., Fung-Leung W. P., Schilham M. W., Kundig T. M., Sambhara S. R., Narendran A. et al. (1991) Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature **353:** 180–184
- 107 Shedlock D. J. and Shen H. (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science **300:** 337–339
- 108 Sun J. C. and Bevan M. J. (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science **300:** 339–342
- 109 Jennings S. R., Bonneau R. H., Smith P. M., Wolcott R. M. and Chervenak R. (1991) CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice. Cell. Immunol. **133:** 234–252
- 110 Riberdy J. M., Christensen J. P., Branum K. and Doherty P. C. (2000) Diminished primary and secondary influenza virusspecific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J. Virol. **74:** 9762–9765
- 111 Marzo A. L., Vezys V., Klonowski K. D., Lee S. J., Muralimohan G., Moore M. et al. (2004) Fully functional memory CD8 T cells in the absence of CD4 T cells. J. Immunol. **173:** 969–975
- 112 Lee B. O., Hartson L. and Randall T. D. (2003) CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment. J. Exp. Med. **198:** 1759–1764
- 113 Montfort M. J., Bouwer H. G., Wagner C. R. and Hinrichs D. J. (2004) The development of functional CD8 T cell memory after Listeria monocytogenes infection is not dependent on CD40. J. Immunol. **173:** 4084–4090
- 114 Sun J. C., Williams M. A. and Bevan M. J. (2004) CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. **5:** 927–933
- 115 Amsen D., Blander J. M., Lee G. R., Tanigaki K., Honjo T. and Flavell R. A. (2004) Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell **117:** 515–526
- 116 Maekawa Y., Tsukumo S., Chiba S., Hirai H., Hayashi Y., Okada H. et al. (2003) Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity **19:** 549–559
- 117 Ansel K. M., Lee D. U. and Rao A. (2003) An epigenetic view of helper T cell differentiation. Nat. Immunol. **4:** 616–623
- 118 Grogan J. L. and Locksley R. M. (2002) T helper cell differentiation: on again, off again. Curr. Opin. Immunol. **14:** 366–372
- 119 Martin-Fontecha A., Thomsen L. L., Brett S., Gerard C., Lipp M., Lanzavecchia A. et al. (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. **5:** 1260–1265
- 120 Kunkel E. J. and Butcher E. C. (2002) Chemokines and the tissue-specific migration of lymphocytes. Immunity 16: 1-4
- 121 Hamann A., Andrew D. P., Jablonski-Westrich D., Holzmann B. and Butcher E. C. (1994) Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J. Immunol. **152:** 3282–3293
- 122 Johansson-Lindbom B., Svensson M., Wurbel M. A., Malissen B., Marquez G. and Agace W. (2003) Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J. Exp. Med. **198:** 963–969
- 123 Svensson M., Marsal J., Ericsson A., Carramolino L., Broden T., Marquez G. et al. (2002) CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J. Clin. Invest. **110:** 1113–1121
- 124 Picker L. J., Kishimoto T. K., Smith C. W., Warnock R. A. and Butcher E. C. (1991) ELAM-1 is an adhesion molecule for skin-homing T cells. Nature **349:** 796–799
- 125 Tietz W., Allemand Y., Borges E., von Laer D., Hallmann R., Vestweber D. et al. (1998) CD4+ T cells migrate into inflamed skin only if they express ligands for E- and P-selectin. J. Immunol. **161:** 963–970
- 126 Campbell D. J. and Butcher E. C. (2002) Rapid acquisition of tissue-specific homing phenotypes by  $CD4(+)$  T cells activated in cutaneous or mucosal lymphoid tissues. J. Exp. Med. **195:** 135–141
- 127 Kantele A., Zivny J., Hakkinen M., Elson C. O. and Mestecky J. (1999) Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. J. Immunol. **162:** 5173–5177
- 128 Dudda J. C., Lembo A., Bachtanian E., Huehn J., Siewert C., Hamann A. et al. (2005) Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue microenvironments. Eur. J. Immunol. **35:** 1056–1065
- 129 Mora J. R., Bono M. R., Manjunath N., Weninger W., Cavanagh L. L., Rosemblatt M. et al. (2003) Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature **424:** 88–93
- 130 Mora J. R., Cheng G., Picarella D., Briskin M., Buchanan N. and Von Andrian U. H. (2005) Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J. Exp. Med. **201:** 303–316
- 131 Calzascia T., Masson F., Berardino-Besson W., Contassot E., Wilmotte R., Aurrand-Lions M. et al. (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity **22:** 175–184
- 132 Iwata M., Hirakiyama A., Eshima Y., Kagechika H., Kato C. and Song S. Y. (2004) Retinoic acid imprints gut-homing specificity on T cells. Immunity 21: 527–538
- 133 Huleatt J. W., Pilip I., Kerksiek K. and Pamer E. G. (2001) Intestinal and splenic T cell responses to enteric Listeria monocytogenes infection: distinct repertoires of responding CD8 T lymphocytes. J. Immunol. **166:** 4065–4073
- 134 Turner S. J., Diaz G., Cross R. and Doherty P. C. (2003) Analysis of clonotype distribution and persistence for an influenza virus-specific CD8+ T cell response. Immunity **18:** 549–559
- 135 Wang X. Z., Stepp S. E., Brehm M. A., Chen H. D., Selin L. K. and Welsh R. M. (2003) Virus-specific CD8 T cells in peripheral tissues are more resistant to apoptosis than those in lymphoid organs. Immunity **18:** 631–642
- 136 Berg E. L., Robinson M. K., Warnock R. A. and Butcher E. C. (1991) The human peripheral lymph node vascular addressin is a ligand for LECAM-1, the peripheral lymph node homing receptor. J. Cell Biol. **114:** 343–349
- 137 Gunn M. D., Tangemann K., Tam C., Cyster J. G., Rosen S. D. and Williams L. T. (1998) A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc. Natl. Acad. Sci. USA **95:** 258–263
- 138 Sallusto F., Lenig D., Forster R., Lipp M. and Lanzavecchia A. (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature **401:** 708–712
- 139 Bouneaud C., Garcia Z., Kourilsky P. and Pannetier C. (2005) Lineage relationships, homeostasis and recall capacities of central- and effector-memory CD8 T cells in vivo. J. Exp. Med. **201:** 579–590
- 140 Unsoeld H., Krautwald S., Voehringer D., Kunzendorf U. and Pircher H. (2002) Cutting edge: CCR7+ and CCR7- memory T cells do not differ in immediate effector cell function. J. Immunol. **169:** 638–641
- 141 Wherry E. J., Teichgraber V., Becker T. C., Masopust D., Kaech S. M., Antia R. et al. (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. **4:** 225–234
- 142 Zaph C., Uzonna J., Beverley S. M. and Scott P. (2004) Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. **10:** 1104–1110
- 143 Campbell J. J., Murphy K. E., Kunkel E. J., Brightling C. E., Soler D., Shen Z. et al. (2001) CCR7 expression and memory T cell diversity in humans. J. Immunol. **166:** 877–884
- 144 Debes G. F., Hopken U. E. and Hamann A. (2002) In vivo differentiated cytokine-producing CD4(+) T cells express functional CCR7. J. Immunol. **168:** 5441–5447
- 145 Chao C. C., Jensen R. and Dailey M. O. (1997) Mechanisms of L-selectin regulation by activated T cells. J. Immunol. **159:** 1686–1694
- 146 Sallusto F., Kremmer E., Palermo B., Hoy A., Ponath P., Qin S. et al. (1999) Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur. J. Immunol. **29:** 2037–2045
- 147 Galkina E., Tanousis K., Preece G., Tolaini M., Kioussis D., Florey O. et al. (2003) L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes. J. Exp. Med. **198:** 1323–1335
- 148 Palecanda A., Walcheck B., Bishop D. K. and Jutila M. A. (1992) Rapid activation-independent shedding of leukocyte Lselectin induced by cross-linking of the surface antigen. Eur. J. Immunol. **22:** 1279–1286
- 149 Reinhardt R. L., Khoruts A., Merica R., Zell T. and Jenkins M. K. (2001) Visualizing the generation of memory CD4 T cells in the whole body. Nature **410:** 101–105
- 150 Masopust D., Vezys V., Marzo A. L. and Lefrancois L. (2001) Preferential localization of effector memory cells in nonlymphoid tissue. Science **291:** 2413–2417
- 151 Hogan R. J., Usherwood E. J., Zhong W., Roberts A. A., Dutton R. W., Harmsen A. G. et al. (2001) Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. **166:** 1813–1822
- 152 Ostler T. and Ehl S. (2002) Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long-lived protective immunity. Eur. J. Immunol. **32:** 2562–2569
- 153 Lanzavecchia A. and Sallusto F. (2002) Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. **2:** 982–987
- 154 Geginat J., Sallusto F. and Lanzavecchia A. (2001) Cytokinedriven proliferation and differentiation of human naive, central memory and effector memory CD4(+) T cells. J. Exp. Med. **194:** 1711–1719
- 155 Geginat J., Lanzavecchia A. and Sallusto F. (2003) Proliferation and differentiation potential of human CD8+ memory Tcell subsets in response to antigen or homeostatic cytokines. Blood **101:** 4260–4266
- 156 Marzo A. L., Klonowski K. D., Bon A. L., Borrow P., Tough D. F. and Lefrancois L. (2005) Initial T cell frequency dictates memory CD8(+) T cell lineage commitment. Nat. Immunol. **6:** 793–799
- 157 Klonowski K. D., Williams K. J., Marzo A. L., Blair D. A., Lingenheld E. G. and Lefrancois L. (2004) Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity **20:** 551–562
- 158 Becker T. C., Coley S. M., Wherry E. J. and Ahmed R. (2005) Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J. Immunol. **174:** 1269–1273